Lexiscan approved for MPI testing Lexiscan (regadenoson injection, from Astellas), a pharmacologic stress agent, is now available for use in radionuclide myocardial perfusion imaging (MPI) for ...
Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Dr. Reddy's is offering ...
Lexiscan Clinical Trials In two identically designed Phase III clinical trials, Lexiscan met primary endpoints for scan agreement rates by showing with 95 percent confidence that MPI studies conducted ...
It looks like Astellas has been unsuccessful in its attempt to block Pfizer's generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the ...
This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. May 13, ...
Point LomaPoint Loma — A new approach to reducing sickle cell anemia’s painful attacks has entered Phase II clinical trials. The drug, Lexiscan, is already approved for diagnosing heart disease.
WASHINGTON, Nov. 20 (UPI) -- The U.S. Food and Drug Administration warns doctors of the rare but serious risk of heart attack and death with use of the cardiac nuclear stress test agents. The cardiac ...
Clinicians should avoid using the imaging agents regadenoson (Lexiscan, Astellas Pharma US) and adenosine (Adenoscan, Astellas Pharma US) for cardiac nuclear stress tests of patients with signs or ...
DEERFIELD, Ill., June 24 Astellas Pharma US, Inc. todayannounced the commercial availability of Lexiscan(TM) (regadenoson) injection,an A2A adenosine receptor agonist, for use as a pharmacologic ...
The U.S. Food and Drug Administration warned physicians on Wednesday that two chemicals used to conduct cardiovascular stress tests can cause heart attacks and death, and it suggested resuscitation ...
PALO ALTO, Calif. and DEERFIELD, Ill., April 10 -- CV Therapeutics and Astellas Pharma US, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Lexiscan(TM) (regadenoson) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results